# Study to Evaluate CCS1477 in Advanced Tumours

> **NCT03568656** · PHASE1,PHASE2 · COMPLETED · sponsor: **CellCentric Ltd.** · enrollment: 220 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer
- Metastatic Breast Cancer
- Non-small Cell Lung Cancer
- Advanced Solid Tumors

## Interventions

- **DRUG:** CCS1477
- **DRUG:** Abiraterone acetate
- **DRUG:** Enzalutamide
- **DRUG:** Darolutamide
- **DRUG:** Olaparib
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03568656
- **Lead sponsor:** CellCentric Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-23
- **Primary completion:** 2025-07-06
- **Final completion:** 2025-07-06
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568656, "Study to Evaluate CCS1477 in Advanced Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03568656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*